Beyond motor neurons: expanding the clinical spectrum in Kennedy's disease by Manzano, R et al.
808 Manzano R, et al. J Neurol Neurosurg Psychiatry 2018;89:808–812. doi:10.1136/jnnp-2017-316961
Review
Beyond motor neurons: expanding the clinical 
spectrum in Kennedy’s disease
Raquel Manzano,1 Gianni Sorarú,2 Christopher Grunseich,3 Pietro Fratta,4 
emanuela Zuccaro,5 Maria Pennuto,5,6 Carlo Rinaldi1
Neurodegeneration
To cite: Manzano R, 
Sorarú G, Grunseich C, et al. J 
Neurol Neurosurg Psychiatry 
2018;89:808–812.
1Department of Physiology, 
Anatomy and Genetics, 
University of Oxford, Oxford, UK
2Department of Neurosciences, 
Neuromuscular Center, 
University of Padova, Padova, 
italy
3Neurogenetics Branch, National 
institute of Neurological 
Disorders and Stroke, National 
institutes of Health, Bethesda, 
Maryland, USA
4Department of Motor 
Neuroscience and Movement 
Disorders, UCL institute of 
Neurology, London, UK
5Department of Biomedical 
Sciences, University of Padova, 
Padova, italy
6Dulbecco Telethon institute, 
Centre for integrative Biology, 
University of Trento, Trento, italy
Correspondence to
Dr Carlo Rinaldi, Department 
of Physiology, Anatomy and 
Genetics, University of Oxford, 
Oxford OX1 3QX, UK;  carlo. 
rinaldi@ dpag. ox. ac. uk
Received 26 October 2017
Revised 21 December 2017
Accepted 21 December 2017
Published Online First 
20 January 2018
AbsTrACT
Kennedy’s disease, or spinal and bulbar muscular atrophy 
(SBMA), is an X-linked neuromuscular condition clinically 
characterised by weakness, atrophy and fasciculations 
of the limb and bulbar muscles, as a result of lower 
motor neuron degeneration. The disease is caused by an 
abnormally expanded triplet repeat expansions in the 
ubiquitously expressed androgen receptor gene, through 
mechanisms which are not entirely elucidated. Over the 
years studies from both humans and animal models have 
highlighted the involvement of cell populations other 
than motor neurons in SBMA, widening the disease 
phenotype. The most compelling aspect of these findings 
is their potential for therapeutic impact: muscle, for 
example, which is primarily affected in the disease, has 
been recently shown to represent a valid alternative 
target for therapy to motor neurons. in this review, we 
discuss the emerging study of the extra-motor neuron 
involvement in SBMA, which, besides increasingly 
pointing towards a multidisciplinary approach for 
affected patients, deepens our understanding of 
the pathogenic mechanisms and holds potential for 
providing new therapeutic targets for this disease.
INTroduCTIoN
Spinal and bulbar muscular atrophy (SBMA) is an 
X-linked neuromuscular condition caused by expan-
sions of a CAG repeat in the androgen receptor (AR) 
gene.1 Disease onset ranges from about 18 to 64 ages, 
with affected males mostly presenting in the fourth 
decade of life with tremor, cramping, proximal and 
distal weakness, and muscle atrophy, secondary to 
lower motor neuron degeneration.2 Involvement of 
the bulbar muscles is a frequent finding, accounting 
for dysarthria and dysphagia, hypernasality and 
perioral fasciculations. Fatigue when chewing and 
occasionally jaw drop are caused by weakness of 
the temporalis and masseter muscles with selective 
preservation of pterygoid muscles.3 Affected subjects 
are at risk of choking on food and aspiration pneu-
monia because of weakness of the bulbar muscles.4 
Compared with other motor neuron diseases, such as 
amyotrophic lateral sclerosis (ALS), disease progres-
sion is relatively slow, with muscle strength declining 
by 2% per year.5 Recent evidence has shown that the 
muscle atrophy in SBMA is not solely secondary to 
the motor neuron degeneration but also consequence 
of a primary myopathic process. In addition, SBMA is 
frequently complicated by other signs and symptoms 
such as gynaecomastia, impotence, testicular atrophy 
and metabolic changes, suggesting a multisystem 
involvement in the disease (figure 1). These features 
frequently manifest early in the disease course and 
can contribute substantially to the morbidity. In this 
review, we discuss the non-motor neuron abnormali-
ties underlining SBMA symptomatology. We propose 
that an improved understanding of these features 
not only could result in better management of the 
patients SBMA, but also has the potential to shed 
new light into the disease pathogenesis, lead to the 
discovery of biomarkers for disease progression and 
open new treatment avenues. 
MeChANIsMs of dIseAse pAThogeNesIs
The AR is a ligand-dependent, ubiquitously 
expressed, transcription factor that belongs to 
the steroid hormone group of nuclear receptors.6 
Following binding to 5α-dihydrotestosterone 
(DHT) and testosterone, AR dimerizes, undergoes 
conformational changes and translocates into the 
nucleus where it recognises androgen response 
elements in the promoter regions of target genes.6 
A complete loss of AR function in males results in 
androgen insensitivity syndrome, in the absence of 
motor neuron involvement,7 favouring a model of 
toxicity in SBMA, where mechanisms of toxic gain 
of function and loss of AR activity coexist. The 
mechanisms of polyQ-AR-mediated toxicity, which 
are yet to be elucidated, are believed to be partly 
due to transcriptional dysregulation, potentially 
resulting in activation of different transcriptional 
programmes in different subcellular populations.8 
Additionally, mutant AR is able to self-associate to 
form soluble oligomers or aggregate into inclusions 
in a ligand-dependent manner.9 10 These aggre-
gates locate mostly in the nucleus and may exert 
toxicity through sequestration of a pool of distinct 
proteins (ie, heat shock proteins or components of 
the ubiquitin-proteasome), AR co-activators and 
other transcription factors,11 which is unique to 
each cell population. These inclusions can be found 
in neuronal as in non-neuronal tissues and visceral 
organs of patients with SBMA.12 Motor neurons are 
particularly sensitive to alterations in the proteo-
stasis network, likely due to their extreme polari-
sation and post-mitotic nature.13 On the other side, 
alterations of protein quality control in muscle, by 
tilting the balance towards increased protein degra-
dation, are likely the underlying cause of the muscle 
atrophy observed in this disease.14
MusCle ATrophy
In the last two decades, an increasing number of 
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figure 1 extra-motor neuron features in spinal and bulbar muscular atrophy.
patient samples have indicated that in SBMA skeletal muscle, 
rather than solely being a bystander of motor neuron degener-
ation, is also primarily involved in the disease pathogenesis and 
represents a target for therapy development. Studies performed 
on patients with SBMA report mildly elevated levels of serum 
creatine kinase (CK)15 and the increase can be detected prior to 
the onset of SBMA clinical symptoms.16 Histological studies on 
muscle biopsies have shown the presence of fibre-type grouping, 
atrophic fibres and angulated fibres, which are observed 
following chronic denervation, together with signs of primary 
myogenic defects, such as necrotic myofibers as well as myofi-
bers with centrally located nuclei.16 17 Androgen-dependent 
impairment of myogenesis was observed in primary myoblasts 
isolated from patients with SBMA, although these cells prolif-
erate and differentiate normally.18 Neurogenic and myopathic 
processes occur in SBMA mouse models.19 20 Notably, muscle 
atrophy foreshadows spinal cord pathology in knock-in SBMA 
mice, underscoring the primary role of skeletal muscles in SBMA 
pathogenesis.21 Tissue-specific expression of mutant AR in mice 
revealed that the sole expression of polyQ-AR in muscle leads 
to a phenotype that resembles SBMA,22 whereas expression in 
peripheral tissues but skeletal muscle prevents development of 
disease manifestations.23 24 Of note, SBMA manifestations in 
transgenic mice can be ameliorated by insulin-like growth factor 
1 treatment or overexpression in muscle, which promotes AR 
degradation through phosphorylation by Akt.19 25 While the 
degree of muscle atrophy seems to be directly correlated to 
the expression levels of AR, how polyQ-AR causes muscular 
atrophy is still largely unknown. Muscular fibres are classified 
into type I slow-oxidative, type IIa fast-oxidative and type IIb 
fast-glycolytic fibres. Typically, muscles contain all types of fibres 
innervated by their corresponding motor neurons. However, the 
ratio between slow and fast fibre types varies between muscles, 
so as to suit each muscle’s function. Muscles of SBMA subjects 
demonstrate glycolytic-to-oxidative switching over the course 
of the disease.26 Remarkably, disease progression in AR113Q 
mice also results in a progressive shift from glycolytic to oxida-
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the preferential vulnerability of glycolytic fibres with respect 
to oxidative fibres.27 Furthermore, lipidomic analyses revealed 
an altered lipid composition in the muscle of knock-in mice 
compared with control animals. This metabolic alteration in 
muscle was associated with altered protein homeostasis, with 
concurrent activation of pathways of protein synthesis and 
degradation.27
These observations obtained in SBMA mice support the idea 
that skeletal muscle primarily degenerates, thereby contributing 
to motor neuron dysfunction and loss.
seNsory NeuropAThy
Along with muscular weakness, patients with SBMA may 
often complain of sensory disturbances, including numbness 
or tingling, and they mainly concerned the distal part of the 
lower limbs.28 29 In most cases, neurological examination reveals 
a slight vibration sense disorder without any abnormalities of 
the other sensory modalities.30 Conversely, neurophysiolog-
ical studies have consistently detected peripheral low or absent 
sensory action potentials (SAPs) in the majority of patients, even 
when motor nerve conduction studies are within the normal 
range.31–33 Histopathology studies showed atrophy of either the 
dorsal root ganglion (DRG) neurons or the large myelinated 
sensory axons in the peripheral nervous system, thus leading 
to a definition of a primary SBMA sensory neuronopathy.34 
Furthermore, nuclear and cytoplasmic accumulation of mutant 
AR has been observed in DRG neurons where it appears related 
to the CAG repeats length.12 31 These pathological changes occur 
in patients with SBMA regardless of the disease duration, clin-
ical severity and presence or absence of diabetes mellitus, indi-
cating that sensory nerve involvement is primarily involved in 
this disease.34 Interestingly, Sobue and colleagues found SAPs 
to be decreased in cases with shorter CAG repeats,31 a finding 
not later confirmed in a larger cohort of Chinese patients with 
SBMA.33 Recent studies have identified a negative correlation 
between the expansion repeat size and the compound muscle 
action potential but not SAP amplitudes.35 On the other hand, 
the involvement of small myelinated and unmyelinated fibres 
demonstrated by means of skin biopsy36 could explain the pres-
ence of neuropathic pain reported by some patients. Lastly, a 
neurophysiological assessment of trigeminal reflexes, including 
the Blink reflex and the jaw-jerk, has suggested a trigeminal 
ganglionopathy.37
AuToNoMIC dysfuNCTIoN
Patients with SBMA do not usually report symptoms suggestive 
of autonomic dysfunctions. However, in a study carried out in 
five SBMA subjects and investigating autonomic cardiovascular 
functions by a series of autonomic function tests, a subclinical 
involvement of both sympathetic and parasympathetic systems 
was observed.38 Previously, autonomic skin denervation with 
impaired sweat testing was reported in two patients.36 These 
findings are in line with the nuclear and cytoplasmic accumu-
lation of expanded AR in neural autonomic regions, including 
hypothalamus, periaqueductal grey, nucleus ambiguus, spinal 
intermediolateral nucleus and sympathetic ganglia.12 Recently, 
a single patient with SBMA carrying 68 CAG repeats has been 
reported to have autonomic disturbances such as reduced 
sweating and difficulties in ejaculation.39
CeNTrAl Nervous sysTeM INvolveMeNT
Recent studies have described subtle brain involvement in 
patients with SBMA. Significantly altered motor-evoked 
potential parameters were reporter in limb and cranial muscles 
in two siblings with clinical presentation and genetic testing 
consistent with diagnosis of SBMA.40 Analyses of white matter 
impairment using diffusion tensor imaging have revealed wide-
spread alterations within the motor system, with a predominant 
deterioration of the corticospinal tract in patients with SBMA.41 
Altogether these studies suggest subclinical involvement of the 
upper motor neuron tract in the disease.
Moreover, glucose hypometabolism in frontal areas of the 
cerebrum was detected in 10 patients with SBMA who under-
went (18)F-fluorodeoxyglucose-positron emission tomography 
studies.42 Interestingly, neuropsychological tests administered 
to 20 patients with SBMA and to age-matched and educa-
tion-matched controls showed distinctive deficits in mentalising, 
as assessed with the Faux Pas Test, although in the context of 
unimpaired neuropsychological performances.43
MeTAbolIC feATures
Evidence of metabolic dysfunction has been identified from 
several studies of patients with SBMA, including changes in 
the levels of glucose, dyslipidaemia and cholesterol.32 33 44 45 An 
evaluation of biochemical profiles from a study of 57 American 
patients found that a majority had elevation of cholesterol and 
low-density lipoprotein (LDL) above the recommended levels.32 
Similar features were identified in a large Italian cohort of 73 
patients evaluated by Querin et al.44 Milder increases in choles-
terol and LDL were detected in a Chinese population, although 
>60% of those evaluated had hypertriglyceridaemia.33 A study 
of 55 Japanese patients found a significant increase in total 
cholesterol levels compared with controls.45 The relationship 
between cholesterol and LDL elevations with other features of 
the disease and lifestyle changes is not clear. Interestingly, disrup-
tions in glucose metabolism and insulin resistance have also been 
reported in the disease. Although serum levels of glucose and 
HbA1c were found to be reduced in SBMA by Nakatsuji et al, 
the homeostasis model assessment of insulin resistance (HOMA-
IR) was significantly elevated in those with the disease compared 
with controls.45 Multivariate analysis identified the variables of 
body mass index (BMI), subcutaneous fat area, visceral fat area 
and testosterone as significant determinants of HOMA-IR.45 This 
study provides evidence of increased insulin resistance in SBMA, 
and the authors identify correlations between HOMA-IR and 
other motor features such as the revised ALS functional rating 
scale, Limb Norris Score and modified quantitative myasthenia 
gravis score. Analysis of skeletal muscle tissue and skin fibroblast 
cells shows reduced protein levels of insulin receptor β subunit 
and insulin receptor substrate 1 in the SBMA samples, which may 
be contributing to the state of insulin resistance. It is not clear if 
the insulin resistance contributes to the neurodegeneration or is 
a consequence of the myopathic pathology. Dysfunction in other 
organ systems such as the liver may also be contributing to the 
changes in metabolism. Evidence of non-alcoholic steatohep-
atitis (NASH), despite normal BMI, was detected by magnetic 
resonance spectroscopy and further confirmed by liver biopsies 
in nearly all of the participants with SBMA evaluated in a recent 
study.46 This evidence, together with difference in gene expres-
sion pathways involved in fatty liver disease between patients 
with SBMA and those with typical NASH, suggests a direct asso-
ciation with the underlying disease.46
bIoCheMICAl ANd horMoNAl feATures
Several abnormalities in serum biochemical measurements have 
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increases in CK, aspartate aminotransferase, alanine amino-
transferase and lactate dehydrogenase. The elevation of these 
markers is indicative of the skeletal muscle pathology in the 
disease. Although these measurements are frequently abnormal, 
their levels have not been found to correlate with functional 
parameters of the disease.32 Low levels of creatinine have also 
been identified and correlate with functional measurements 
such as grip strength and the 6 min walk distance.47 The creati-
nine measurements may be a useful marker for tracking disease 
progression as these levels have been known to be associated with 
muscle mass. Serum creatinine levels have also been found to be 
lower in SBMA than patients with ALS who have similar muscle 
mass loss.48 Evaluation of the skeletal muscle from autopsy 
specimens identified decreased expression of the creatine trans-
porter SLC6A8, providing a potential mechanism for the reduc-
tion in creatine levels in addition to the neurogenic aetiology.48 
Measurements of the ligand for the AR, testosterone and its more 
potent derivative DHT have also been investigated in patients 
with SBMA.4 32 33 44 Similarly to mice expressing polyQ-AR, 
which display decreased fertility, testicular atrophy and partial 
androgen insensitivity,21 patients frequently experience features 
of androgen loss of function including gynaecomastia, sexual 
dysfunction and testicular atrophy. Although most patients have 
androgen levels that fall within the normal reference range, 
some fall either above or below this reference range.32 33 44 47 An 
evaluation of the androgen sensitivity index (testosterone levels 
multiplied by luteinizing hormone) found that about one-third 
of patients had increased index values,44 indicating a state of 
androgen resistance. Androstenedione, an intermediate in the 
synthesis of testosterone, was found to be reduced in another 
group of patients with SBMA.32 Multivariate regression analysis 
has identified that total testosterone levels positively correlate 
with quality of life as measured by the SF-36v2 questionnaire, 
muscle strength and activities of daily living. These findings 
suggest that in addition to activating AR toxicity, androgens may 
also be yielding potential anabolic-strengthening effects.
CArdIAC AbNorMAlITIes
Although primary muscle involvement is a clear feature of 
SBMA, no detectable morphological and structural abnormal-
ities appear in the myocardium, differently from numerous 
genetic myopathies. The typical nuclear AR accumulation, which 
is found in immunohistochemistry across numerous tissues, is 
also present in the myocardium and has potentially been linked 
to rhythm abnormalities which have been described in a signif-
icant proportion of SBMA sufferers. Araki et al first described 
ST alterations in ECGs of patients with SBMA, with Brugada 
syndrome-like alterations being the most common and found 
in 12% of cases.49 These abnormalities have been subsequently 
validated by other groups in different populations, although at 
lower frequency.44 Brugada syndrome can lead to sudden death, 
and screening of these abnormalities should become routine in 
patients with SBMA. Importantly, these abnormalities can be 
detected with ECG, and a simple modification in the conven-
tional lead position significantly improves the detection of this 
defect and is recommended.50
urINAry INvolveMeNT
The genitourinary tract involvement is among the previously 
unrecognised non-neuromuscular features of SBMA. Querin 
et al investigated a cohort of 71 patients with SBMA using 
the International Prostate Symptom Score (IPSS), followed by 
urodynamic and ultrasound investigations, when abnormalities 
in IPSS were found.44 Forty per cent of cases were either moder-
ately or severely symptomatic for lower urinary tract symptoms 
(LUTS). The most prevalent finding was that of a bladder outlet 
obstruction in the absence of any indication for benign prostatic 
hyperplasia from biochemical and ultrasound investigations. 
It is not currently known whether LUTS are due to androgen 
insensitivity or a toxic AR expansion gain of function. It is none-
theless intriguing that knock-in mice carrying the AR expansion 
die due to alterations in the neuromuscular bladder axis, which 
determine acute urinary retention in the absence of a physical 
obstruction,21 thus further supporting the direct mechanistic link 
between the AR expansion and urinary dysfunction.
CoNClusIoNs
In SBMA, as in other genetic conditions caused by mutations 
in ubiquitously expressed genes, the clinical picture is the result 
of a complex interplay between differentially affected tissues, 
which struggle to cooperate to maintain homeostasis.
Extra-motor neuron features in SBMA, such as primary 
muscle atrophy or hormonal abnormalities, are emerging as 
clinically highly impactful in patients’ quality of life and disease 
progression. Their thorough investigations are proving critical 
for a number of reasons. First, they may provide important 
insights into common mechanisms of pathogenesis. Second, 
the peripheral abnormalities may offer the opportunity for 
direct functional assessments and repetitive samplings, therefore 
representing potentially exploitable biomarkers to track disease 
progression and/or response to therapy. Lastly, disentangling 
the underlying molecular mechanisms of this highly integrated 
inter-tissues cross-talk may offer unparalleled opportunities for 
therapeutic interventions in the near future.
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